Rep. Mike Fitzpatrick (R-Pa.), a staunch advocate for mandating individual reporting of adverse events by physicians
Doug Lowy will continue to lead NCI in his role as acting director in 2017 unless president-elect Donald Trump decides to appoint a different, new director.
The Senate approved the 21st Century Cures Act, a wide-ranging bill that authorizes $1.8 billion over seven years for cancer research as well as $500 million over the next decade for FDA to streamline drug and device approval processes.
Operating losses at MD Anderson Cancer Center ballooned again in October—swelling to $60.9 million on top of September's $41.5 million.
The House of Representatives has approved a revised version of the 21st Century Cures Act, a comprehensive $6.3 billion health care reform measure that would fund the National Cancer Moonshot Initiative and amend FDA standards for regulating drugs and devices.
In an unusual move, the National Cancer Advisory Board fired off a letter urging Congress to authorize additional “moonshot” funds, and—just as importantly—to place these new funds in the NCI budget.
Amgen announced that a phase III study evaluating XGEVA (denosumab) versus zoledronic acid met the primary endpoint of non-inferiority (hazard ratio = 0.98, 95 percent CI, 0.85 - 1.14) in delaying the time to first on-study skeletal-related event in patients with multiple myeloma.
Sixty percent of men whose testicular cancer returned were cured with high-dose chemotherapy and a stem cell transplant, according to research published by Indiana University researchers.
Blue Earth Diagnostics Ltd. announced the peer-reviewed publication of results from a phase III clinical trial of Axumin (fluciclovine F 18) injection.
